From GlobeNewswire: 2025-05-05 06:45:00

BioNTech reported progress in its oncology pipeline, focusing on two key programs: BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1, and mRNA cancer immunotherapies. Financial results for Q1 2025 showed revenues of €182.8 million, net loss of €415.8 million, and €15.9 billion in cash. Full-year 2025 guidance confirmed, with revenues expected to range from €1,700 – €2,200 million. A new CFO, Ramón Zapata-Gomez, was appointed to the Management Board effective July 1, 2025. BioNTech also completed the acquisition of Biotheus, obtaining rights to their pipeline.

In the oncology pipeline, BNT327 showed promising anti-tumor activity and a manageable safety profile in Phase 2 trials for small cell lung cancer. Preliminary data for the combination of BNT327 with various ADC candidates presented at AACR showed anti-tumor activity in patients with solid tumors. BNT116, an mRNA cancer immunotherapy, exhibited anti-tumor activity and consistent immune response induction in frail patients with NSCLC at AACR. Two ADC candidates, BNT324/DB-1311 and BNT325/DB-1305, received Fast Track designation for advanced prostate cancer and ovarian cancer, respectively.

BioNTech and Pfizer have developed COVID-19 vaccines that received regulatory approvals in over 40 countries. They are now preparing for a variant-adapted COVID-19 vaccine for the 2025/2026 season. Financial statements for Q1 2025 showed an operating loss of €534.1 million, with revenues primarily driven by the COVID-19 vaccine collaboration. The company’s strong cash position enables continued investment in R&D and business scaling for oncology product development.

BioNTech invites investors to a conference call and webcast on May 5, 2025, to discuss financial results and corporate updates for Q1 2025. The company remains committed to advancing its oncology pipeline, with a focus on innovative immunotherapies and strategic partnerships. With a solid financial foundation and ongoing research progress, BioNTech aims to lead in biotech innovation and oncology product development by 2030.



Read more at GlobeNewswire:: BioNTech Announces First Quarter 2025 Financial Results and